Prime Highlights
- Alyftrek sales skyrocketed nearly sevenfold year-on-year to $424.4 million in its first full quarter post-approval.
- Non-opioid painkiller Journavx crossed one million total prescriptions, with over 350,000 filled in Q1 alone.
Key Facts
- Vertex Pharmaceuticals is a dominant player in cystic fibrosis treatment with multiple approved therapies.
- Cystic fibrosis is a rare genetic disorder causing severe respiratory and digestive complications.
Background
Vertex Pharmaceuticals surpassed Wall Street’s first-quarter profit expectations, powered by a dramatic rise in sales of its newly launched cystic fibrosis treatment, Alyftrek.
The Boston-based company reported adjusted earnings of $4.47 per share for the January–March quarter, topping analyst estimates of $4.31 per share. Quarterly revenue rose 8% to $2.99 billion, slightly below the expected $3.02 billion.
Alyftrek, a once-daily triple combination therapy approved in late December 2024, generated $424.4 million in sales during the quarter, a surge of nearly 687% compared to $53.9 million in the same period a year earlier. It is an effective treatment for cystic fibrosis, which is a rare congenital disease that hinders the transport of salts and water in body cells, leading to serious problems with the lungs and digestion.
The cystic fibrosis treatment Trikafta developed by Vertex generated $2.35 billion in revenue, which fell short of the $2.64 billion revenue projection established by analysts. The gap signals that Alyftrek is increasingly cannibalising Trikafta’s patient base as physicians shift prescriptions to the newer treatment.
Beyond cystic fibrosis, Vertex is actively building its pipeline. Its non-opioid pain treatment, Journavx, launched in early March last year and has since crossed one million total prescriptions. In the first quarter alone, prescriptions exceeded 350,000, generating $29 million in revenue. It also owns Casgevy, which is an approved gene therapy that can treat sickle cell disease and transfusion-dependent beta-thalassemia.
The corporation kept its revenue outlook for the year unchanged at $12.95 billion to $13.1 billion despite the underperformance of Trikafta.
